Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients With Advanced Solid Tumors

NCT05268666 is registered in ClinicalTrials.gov with Jubilant Therapeutics Inc. as lead sponsor.

NCT NCT05268666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05268666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients With Advanced Solid Tumors
Lead sponsor
Jubilant Therapeutics Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 8, 2022
Completion date
August 31, 2025
Enrollment
126 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic solid tumor